Where can I find news about CBIH?

The latest headlines, third-party analysis, and SEC filings for Cannabis Bioscience International Holdings, Inc. (CBIH) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are CBIH's SEC filings?

Cannabis Bioscience International Holdings, Inc. (CBIH)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are CBIH's earnings call transcripts?

Full earnings call transcripts for Cannabis Bioscience International Holdings, Inc. (CBIH) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

CBIH

Cannabis Bioscience International Holdings, Inc.

OTC·Drug Manufacturers, Specialty & Generic · Healthcare

$0.00$0.00+0.00%

Market cap$1.16M·Market closed·Aug 25 8:00 PM UTC

News & Analysis

CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
Houston, Texas--(Newsfile Corp. - July 6, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on
feeds.newsfilecorp.comJul 6, 2026 · 7:00 AM
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
Houston, Texas--(Newsfile Corp. - June 22, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the beginning of a new commercial chapter for VitaCookies with the signing of its first licensing agreement. This milestone moves VitaCookies from internal development toward commercial execution, positioning the brand as a structured growth opportunity built on CBIH's formulations, operational know-how, quality standards, and wellness-oriented vision.
newsfilecorp.comJun 22, 2026 · 7:00 AM
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
Houston, Texas--(Newsfile Corp. - June 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading under the ticker symbol CBIH, today announced a new chapter in its PTSD-focused research journey, marked by the completion of its patent-related work and the continued exploration of the scientific relationship between cannabinoids and psilocybin in relation to trauma, memory, emotional regulation, and recovery. PTSD affects veterans, first responders, survivors of sexual assault and domestic violence, children exposed to trauma, families, and communities.
newsfilecorp.comJun 15, 2026 · 7:00 AM
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading
feeds.newsfilecorp.comJun 8, 2026 · 7:00 AM
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on
feeds.newsfilecorp.comJun 1, 2026 · 7:00 AM
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on
feeds.newsfilecorp.comJan 12, 2026 · 7:00 AM
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on
feeds.newsfilecorp.comDec 29, 2025 · 7:00 AM
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry
feeds.newsfilecorp.comDec 22, 2025 · 7:00 AM

SEC Filings

253G2
Jul 1, 2026View on SEC
253G2
May 21, 2026View on SEC
10-Q
Apr 16, 2026View on SEC
253G2
Apr 15, 2026View on SEC
NT 10-Q
Apr 14, 2026View on SEC
QUALIF
Apr 14, 2026View on SEC

Frequently Asked Questions About CBIH

Where can I find news about CBIH?: The latest headlines, third-party analysis, and SEC filings for Cannabis Bioscience International Holdings, Inc. (CBIH) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are CBIH's SEC filings?: Cannabis Bioscience International Holdings, Inc. (CBIH)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are CBIH's earnings call transcripts?: Full earnings call transcripts for Cannabis Bioscience International Holdings, Inc. (CBIH) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Cannabis Bioscience International Holdings, Inc.

Frequently Asked Questions About CBIH

Cannabis Bioscience International Holdings, Inc.

CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings

Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement

CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research

CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers

CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence

CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Frequently Asked Questions About CBIH

CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings

Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement

CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research

CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers

CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence

CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities